Key result
The newly developed centrifugal pump demonstrated improved antithrombogenicity and low hemolysis, with the NCVC-2 model achieving a hemolysis index of 0.006 g/100 L and supporting goats for up to 182 days.
Population
In vitro (heparinized fresh goat blood) and in vivo (goats weighing 52-75 kg)
Design
Preclinical
Follow-up
up to 182 days
Authors
Loading...
Hypothesis-generating for antithrombogenic centrifugal pumps in chronic MCS; leaves open human translation pending clinical trials.
Iterative design improvements to a centrifugal pump reduced hemolysis and improved antithrombogenicity, allowing for up to 182 days of continuous left heart bypass in a goat model.
Taenaka et al. (1996) studied Chronic circulatory support (animal model) (n=16). Centrifugal pump (NCVC-0, NCVC-1, NCVC-2) was evaluated on Hemolysis index and in vivo pumping days. The newly developed centrifugal pump demonstrated improved antithrombogenicity and low hemolysis, with the NCVC-2 model achieving a hemolysis index of 0.006 g/100 L and supporting goats for up to 182 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: